SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications
NAR Cancer · 2026
DOI: 10.1093/narcan/zcag019 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2026. Verfasst von Marcela Briones-Martin-Del-Campo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, San Francisco, CA 94158, United States. Hauptthemen laut MEDLINE: Sarcoma, Ewing, RNA, Small Nucleolar, RNA, Long Noncoding, Bone Neoplasms. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Over 90% of Ewing sarcomas (EWS) are driven by the EWS–FLI1 fusion oncoprotein. EWS–FLI1 acts as a pioneer transcription factor, altering the expression of hundreds of genes including many long non-coding RNAs (lncRNAs). The role of these lncRNAs in the oncogenesis of EWS is mostly unknown. We developed a CRISPR interference (CRISPRi) strategy to knock down expression of lncRNA loci expressed in EWS and evaluate their effect on proliferation in vitro and tumor growth in vivo. While most lncRNA knockdown had minimal effect on cell proliferation, selective inhibition of SNHG1, SNHG12, and SNHG30 significantly reduced both proliferation of Ewing cells in vitro and the growth of Ewing tumors in vivo. These results were validated by individual knockdown followed by RNA-seq to assess their functional impact. We observed a decrease in post-transcriptional modifications (2′-O-methylation and pseudouridylation) at specific rRNA positions known to be guided by snoRNAs encoded in SNHG1 and SNHG12. Collectively, we demonstrate that expression of SNHG1, SNHG12, and SNHG30 in EWS cells contributes to the maintenance of cancer cell fitness via their role in intron-processed snoRNA genes. Thus, post-transcriptional regulation of rRNA may be a previously underappreciated consequence of EWS–FLI1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of California, San Francisco, CA 94158, United States.
- Epitranscriptomics and RNA Sequencing Core Facility, Université de Lorraine, CNRS, INSERM, IBSLor (UAR2008/US40), Nancy F-54000, France.
- IMoPA (UMR7365), CNRS, Université de Lorraine, Nancy F-54000, France.
- Department of Pediatrics, Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, United States.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, United States.
- Department of Urology, University of California, San Francisco, CA 94158, United States.
ORCID-Profile: Marcela Briones-Martin-Del-Campo, Yuri Motorin, Max A Horlbeck, Kimberly Stegmaier, E Alejandro Sweet-Cordero
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- Sunbeam Foundation
Zitieren
APA
Briones-Martin-Del-Campo, M., Lee, A. G., Dinh, T., Marchand, V., Motorin, Y., Román, M., Bi, Q., Leung, S. G., Horlbeck, M. A., Sayles, L. C., Seong, B. K. A., Gilbert, L., Stegmaier, K., & Sweet-Cordero, E. A. (2026). SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications. NAR Cancer. https://doi.org/10.1093/narcan/zcag019
Vancouver
Briones-Martin-Del-Campo M, Lee AG, Dinh T, Marchand V, Motorin Y, Román M, et al. SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications. NAR Cancer. 2026. doi:10.1093/narcan/zcag019
BibTeX
@article{BrionesMartinDelCampo2026,
author = {Briones-Martin-Del-Campo, Marcela and Lee, Alex G and Dinh, Truc and Marchand, Virginie and Motorin, Yuri and Román, Marta and Bi, Qiuli and Leung, Stanley G and Horlbeck, Max A and Sayles, Leanne C and Seong, Bo Kyung Alex and Gilbert, Luke and Stegmaier, Kimberly and Sweet-Cordero, E Alejandro},
title = {SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications},
journal = {NAR Cancer},
year = {2026},
doi = {10.1093/narcan/zcag019}
}
EUVIMED